



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

16 June 2017
EMA/CAT/344401/2017
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Advanced Therapies (CAT)

Agenda for the meeting on 15-16 June 2017

Chair: Martina Schübler-Lenz; Vice-Chair: Ilona Reischl

15 June 2017, 09:00 – 14:00hrs

16 June 2017, 09:00 – 14:00hrs

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
1.4.	Technical information	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.3.	Day 180 list of outstanding issues	5
2.4.	Day 120 list of questions	5
2.5.	Day 80 assessment reports	5
2.6.	Update on ongoing initial applications.....	5
2.7.	New applications	6
2.7.1.	Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor – Orphan - EMA/H/C/0004480.....	6
2.8.	Withdrawal of initial marking authorisation application	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	6
2.10.	GMP and GCP inspections requests	6
2.11.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	6
2.11.1.	Holoclar – <i>Ex vivo</i> expanded autologous human corneal epithelial cells containing stem cells - EMEA/H/C/002450/II/0012/G	6
2.12.	Other Post-Authorisation Activities	6
2.12.1.	Glybera - alipogene tiparvec - Orphan - EMEA/H/C/002145/SOB/002.8.....	6
2.12.2.	Glybera - alipogene tiparvec - Orphan - EMEA/H/C/002145/SOB/002.9.....	7
2.12.3.	Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) complementary deoxyribonucleic acid (cDNA) sequence - Orphan - EMEA/H/C/003854/PSUSA/10505/201611	7
3.	Certification of ATMPs	7
3.1.	Opinion.....	7
3.2.	Day 60 Evaluation Reports.....	7
3.3.	New Applications	7
4.	Scientific Recommendation on Classification of ATMPs	7
4.1.	New requests – Appointment of CAT Coordinator	7
4.1.1.	Autologous adipose derived mesenchymal stem cells - EMA/H0004813	7

4.2.	Day 30 ATMP scientific recommendation	8
4.2.1.	Stromal vascular fraction cells for autologous use - EMA/H0004838	8
4.2.2.	Autologous human keratinocytes - EMA/H0004841	8
4.2.3.	Autologous human chondrocytes - EMA/H0004840	8
4.2.4.	Allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) - H0004839	8
4.3.	Day 60 revised scientific recommendation (following list of questions)	8
4.4.	Finalisation of procedure	8
4.4.1.	Autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (sTRAIL) - EMA/H0004820.....	8
4.4.2.	Replication incompetent adenoviral serotype 5 vector encoding the human interleukin-12 p70 (hIL-12) transgene under the control of the activator ligand, veledimex - EMA/H0004805 ..	9
4.4.3.	Allogenic human mesenchymal stem cells - Mesenchymal stem cells isolated from umbilical cord - EMA/H0004815	9
4.4.4.	Autologous adipose derived mesenchymal stem cells - EMA/H0004798	9
4.4.5.	Cultured allogeneic Wharton jelly derived mesenchymal stem cells - EMA/H0004796	9
4.4.6.	Cultured autologous adipose derived mesenchymal stem cells - EMA/H0004799.....	9
4.4.7.	Cultured autologous adipose derived regenerative mesenchymal stem cells - EMA/H0004797	9
4.4.8.	Cultured autologous Wharton jelly derived mesenchymal stem cells - EMA/H0004795.....	10
4.4.9.	Adenovirus-associated viral vector serotype 5 containing CRISPR Cas9 and guide ribonucleic acids (RNAs) targeting intron 26 of the centrosomal protein 290 gene (AAV5-GRK1-SauCas9-CEP290gRNA 323/64) - EMA/H0004818	10
4.4.10.	Allogeneic unexpanded amniotic fluid derived cells suspended with dried and cryofractured amniotic tissue - EMA/H0004816	10
4.4.11.	Human autologous stromal vascular fraction (SVF) - EMA/H0004822	10
4.4.12.	Human autologous adipose-derived stromal/stem cells (ADSCs) - EMA/H0004823	10
4.4.13.	Bilayer, engineered, collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts - EMA/H0004817	10
4.4.14.	Resorbable, viscoelastic matrix for use with autologous stromal vascular fraction (SVF) - EMA/H0004819	11
4.5.	Follow-up and guidance.....	11
5.	Scientific Advice	11
5.1.	New requests – appointment of CAT Coordinators.....	11
5.2.	CAT reports.....	11
5.3.	List of Issues	11
5.4.	Finalisation of SA procedures	11
6.	Pre-Authorisation Activities	11
6.1.	Paediatric investigation plans.....	11
6.2.	ITF briefing meetings in the field of ATMPs	11
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	11

6.3.1.	Month 0 - Start of the procedure	11
6.3.2.	Month 1 – Discussion of eligibility	11
6.3.3.	Month 2 – Recommendation of eligibility.....	12
6.3.4.	Month 3 – Nomination of Rapporteurs	12

7. Organisational, regulatory and methodological matters 12

7.1.	Mandate and organisation of the CAT	12
7.1.1.	CAT membership	12
7.1.2.	Strategic Review & Learning meeting – Malta, June 2017	12
7.1.3.	Good manufacturing practice (GMP) requirements for ATMPs	12
7.1.4.	Advanced training on best use of EMA’s technical tools for the committee’s members	12
7.2.	Coordination with EMA Scientific Committees.....	12
7.2.1.	Committee for Medicinal Products for Human Use (CHMP)	12
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	13
7.3.1.	Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP)	13
7.3.2.	Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells	13
7.4.	Cooperation within the EU regulatory network.....	13
7.4.1.	Orphan similarity for ATMPs	13
7.5.	Cooperation with international regulators	13
7.5.1.	ATMP cluster teleconference with FDA, Health Canada and PMDA.....	13
7.6.	CAT work plan	14
7.6.1.	Expert meeting on adeno-associated viral vectors, 6 September 2017, EMA, London	14
7.7.	Planning and reporting	14
7.7.1.	Planning estimates of forthcoming ATMP MAAs	14
7.8.	Others	14
7.8.1.	Health and Environmental Sciences Institute (ILSI) annual meeting, May 2016	14

8. Any other business 14

9. Explanatory notes 15

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 15-16 June 2017. See June 2017 CAT minutes (to be published post July 2017 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 15-16 June 2017 meeting

1.3. Adoption of the minutes

CAT minutes for 10-12 May 2017 meeting

1.4. Technical information

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.7.1. Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor – Orphan - EMA/H/C/0004480

Kite Pharma UK Ltd; Intended for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) who have not responded to their prior therapy, or have had disease progression after autologous stem cell transplant (ASCT)

Scope: CAT conclusion on the evaluation of the request for accelerated assessment

Action: for adoption

2.8. Withdrawal of initial marking authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Holoclar – *Ex vivo* expanded autologous human corneal epithelial cells containing stem cells - EMEA/H/C/002450/II/0012/G

Chiesi Farmaceutici S.p.A.

Rapporteur: Egbert Flory; CHMP Coordinator: Jan Mueller-Berghaus

Scope: quality Opinion

Action: for adoption

2.12. Other Post-Authorisation Activities

2.12.1. Glybera - alipogene tiparvovec - Orphan - EMEA/H/C/002145/SOB/002.8

UniQure biopharma B.V.; Indicated for the long term correction of lipoprotein lipase deficiency, to control or abolish symptoms and prevent complications in adult patients clinically diagnosed with lipoprotein lipase deficiency (LPLD)

Rapporteur: Christiane Niederlaender; Co-Rapporteur: Egbert Flory; CHMP Coordinators: Greg Markey, Jan Mueller-Berghaus

Scope: Rapporteur's report of the MAH's response to SOB-002.6 as adopted in February 2017

Action: for adoption

2.12.2. Glybera - alipogene tiparovec - Orphan - EMEA/H/C/002145/SOB/002.9

uniQure biopharma B.V. ; Indicated for the long term correction of lipoprotein lipase deficiency, to control or abolish symptoms and prevent complications in adult patients clinically diagnosed with lipoprotein lipase deficiency (LPLD)

Rapporteur: Christiane Niederlaender; Co-Rapporteur: Egbert Flory; CHMP Coordinators: Greg Markey, Jan Mueller-Berghaus

Scope: Rapporteur's report of the MAH's response to SOB-002.7 as adopted in February 2017

Action: for adoption

2.12.3. Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) complementary deoxyribonucleic acid (cDNA) sequence - Orphan - EMEA/H/C/003854/PSUSA/10505/201611

GlaxoSmithKline Trading Services

Rapporteur: Christiane Niederlaender; Co-Rapporteur: Sol Ruíz; CHMP Coordinators: Robert H. Hemmings, Concepción Prieto Yerro; PRAC Rapporteur: Sabine Straus

Scope: Pharmacovigilance: evaluation of a periodic safety update report single assessment (PSUSA) procedure

Action: for information

Note: PRAC adopted a recommendation at its 6-9 June 2017 meeting

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Autologous adipose derived mesenchymal stem cells - EMA/H0004813

Intended for the treatment of chronic wound

Scope: postponement of discussion and adoption of the scientific recommendation by one month to July 2017

Action: for information

Note: start of procedure was postpone awaiting additional information from the applicant

4.2. Day 30 ATMP scientific recommendation

4.2.1. Stromal vascular fraction cells for autologous use - EMA/H0004838

Intended for the relief of symptoms of osteoarthritis

Scope: scientific recommendation

Action: for adoption

4.2.2. Autologous human keratinocytes - EMA/H0004841

Intended for the treatment of burns and chronic, severe wounds

Scope: scientific recommendation

Action: for adoption

4.2.3. Autologous human chondrocytes - EMA/H0004840

Intended for the repair of single symptomatic cartilage defect of the knee or ankle

Scope: scientific recommendation

Action: for adoption

4.2.4. Allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) - H0004839

Intended for the treatment of atopic dermatitis

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (sTRAIL) - EMA/H0004820

Intended for the treatment of TRAIL-sensitive cancers such as Ewing sarcoma and pancreatic ductal adenocarcinoma

Scope: minor comments received from the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.2. [Replication incompetent adenoviral serotype 5 vector encoding the human interleukin-12 p70 \(hIL-12\) transgene under the control of the activator ligand, veledimex - EMA/H0004805](#)

Intended for the treatment of recurrent or progressive glioblastoma

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.3. [Allogenic human mesenchymal stem cells - Mesenchymal stem cells isolated from umbilical cord - EMA/H0004815](#)

Intended for the treatment of chronic obstructive pulmonary disease

Scope: minor comments received from the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.4. [Autologous adipose derived mesenchymal stem cells - EMA/H0004798](#)

Intended for the treatment of autoimmune drug resistant epilepsy

Scope: minor editorial comments received from the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.5. [Cultured allogeneic Wharton jelly derived mesenchymal stem cells - EMA/H0004796](#)

Intended for the treatment of amyotrophic lateral sclerosis (ALS)

Scope: minor editorial comments received from the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.6. [Cultured autologous adipose derived mesenchymal stem cells - EMA/H0004799](#)

Intended for the treatment of autoimmune drug resistant epilepsy

Scope: minor editorial comments received from the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.7. [Cultured autologous adipose derived regenerative mesenchymal stem cells - EMA/H0004797](#)

Intended for the treatment of autoimmune drug resistant epilepsy

Scope: minor editorial comments received from the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.8. Cultured autologous Wharton jelly derived mesenchymal stem cells - EMA/H0004795

Intended for the treatment of amyotrophic lateral sclerosis (ALS)

Scope: revised ATMP classification report following comments by the European Commission

Action: for adoption

4.4.9. Adenovirus-associated viral vector serotype 5 containing CRISPR Cas9 and guide ribonucleic acids (RNAs) targeting intron 26 of the centrosomal protein 290 gene (AAV5-GRK1-SauCas9-CEP290gRNA 323/64) - EMA/H0004818

Intended for the treatment of patients aged 3 years and older with Leber congenital amaurosis type 10 (LCA10) caused by a homozygous or compound heterozygous intron 26 mutation, c.2991+1655 A>G, in the CEP290 gene

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.10. Allogeneic unexpanded amniotic fluid derived cells suspended with dried and cryofractured amniotic tissue - EMA/H0004816

Intended for the treatment of chronic wound care

Scope: minor editorial comments received from the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.11. Human autologous stromal vascular fraction (SVF) - EMA/H0004822

Intended for the treatment of articular cartilage and bone defects

Scope: revised ATMP classification report following comments by the European Commission

Action: for adoption

4.4.12. Human autologous adipose-derived stromal/stem cells (ADSCs) - EMA/H0004823

Intended for the treatment of articular cartilage and bone defects

Scope: revised ATMP classification report following comments by the European Commission

Action: for adoption

4.4.13. Bilayer, engineered, collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts - EMA/H0004817

Intended for the treatment of partial deep dermal and full thickness burn wounds

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

4.4.14. Resorbable, viscoelastic matrix for use with autologous stromal vascular fraction (SVF) - EMA/H0004819

A resorbable matrix to be used for the delivery of autologous SVF adipose derived cells for the treatment of HIV-related facial lipoatrophy

Scope: minor editorial comments received from the European Commission. Final ATMP scientific recommendation

Action: for information

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Coordinators

5.2. CAT reports

5.3. List of Issues

5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Month 3 – Nomination of Rapporteurs

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Scope: membership changes

Austria: Corina Spreitzer - nomination as member on 01 April 2017

Clinicians' representative: Willem Eduard Fibbe - nomination as alternate on 11 May 2017

Clinicians' representative: Francisco Blanco García - nomination as alternate on 11 May 2017

Action: for information

7.1.2. Strategic Review & Learning meeting – Malta, June 2017

Scope: feedback from the meeting that took place in Gozo, Malta on 1-2 June 2017 under the auspices of the Maltese Presidency of the Council of the European Union

Action: for information

7.1.3. Good manufacturing practice (GMP) requirements for ATMPs

Scope: discussion of the GMP for ATMP guideline following the joint inspectors-CAT drafting group of 26 April 2017

Action: for discussion

7.1.4. Advanced training on best use of EMA's technical tools for the committee's members

Scope: advanced training session at the July 2017 meeting on best use of technical tools for the committee's members.

Action: for information

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the May 2017 meeting

Action: for information

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

Scope: agenda of PCWP/HCPWP joint meeting to take place on 27-28 June 2017

Action: for information

7.3.2. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells

CAT topic leader: Marcos Timón; CAT members: Ilona Reischl, Paula Salmikangas, Christiane Niederlaender, Belaïd Sekkali, Margarida Menezes Ferreira, Tiina Palomäki, Guido Pantè, Matthias Renner, Brigitte Anliker, Nicolaoas Anagnou

Scope: concept paper for the revision of the guideline

Action: for adoption

7.4. Cooperation within the EU regulatory network

7.4.1. Orphan similarity for ATMPs

CAT drafting group: Simona Badoi, Violaine Closson-Carella, Michele Lipucci, Margarida Menezes-Ferreira, Christiane Niederlaender, Ilona Reischl, Paula Salmikangas

Scope: Reflection from the perspective of ATMPs on the concept of 'similar active substance' as referred to in Art 3(3)c of Reg (EC) No 847/2000 of April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concept 'similar medicinal product' and 'clinical superiority'. Review of comments received from the public consultation.

Action: for discussion

Consultation document published by the European Commission

http://ec.europa.eu/health/sites/health/files/files/orphanmp/2016_07_pc_orphan/2016_07_consultation_paper.pdf

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with FDA, Health Canada and PMDA

Postponed to July 2017

The teleconference will take place right after the end of the first day of the plenary meeting

CAT: Martina Schübler-Lenz

Scope: draft agenda

Action: for adoption

7.6. CAT work plan

7.6.1. Expert meeting on adeno-associated viral vectors, 6 September 2017, EMA, London

CAT: Jan Mueller-Berghaus, Rune Kjekken

Scope: updated list of questions. For review and comments by CAT member by Wednesday 12 June 2017

Action: for adoption

Note: the list of questions was updated following the focus group in the margins of the Strategic & Review meeting that took place on 31 May – 2 June 2017. Following adoption by CAT, it will be forwarded to the external experts.

7.7. Planning and reporting

7.7.1. Planning estimates of forthcoming ATMP MAAs

Scope: Q2/2017 update of the business pipeline report for the human scientific committees

Action: for information

7.8. Others

7.8.1. Health and Environmental Sciences Institute (ILSI) annual meeting, May 2016

CAT: Carla Herberts

Scope: feedback from participating CAT member Carla Herberts on the initiation and subsequent activities of the ILSI-HESI emerging issue committee on Cell Therapy - TRacking, Circulation, & Safety (CT-TRACS)

Action: for information

8. Any other business

No items

Date of next CAT meeting:

12-14 July 2017

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Applicant

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices

SAG-O: Scientific Advisory Group Oncology
SAWP: Scientific Advice Working Party
SR: Summary Report
SWP: Scientific Working Party
SME: Small and medium size enterprises
SmPC: Summary of Products Characteristics
TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion,

which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/